Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavyret and Zetia for HCV Prevention in Solid Organ Transplant Recipients
NCT04508907Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2020
- Primary completion
- Nov 2025
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of glecaprevir, ezetimibe in hepatitis C (HCV), sponsored by Mayo Clinic. Started Sep 2020; status: completed.
02
Drugs
glecaprevirezetimibe
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04508907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508907.